<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175212</url>
  </required_header>
  <id_info>
    <org_study_id>DART01/05</org_study_id>
    <nct_id>NCT02175212</nct_id>
  </id_info>
  <brief_title>Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer</brief_title>
  <acronym>AADLPC</acronym>
  <official_title>Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is a phase III randomized and multicentric trial evaluating the potential
      additional impact effect of two years adjuvant androgen deprivation when combined with
      neoadjuvant (4 months) and high-dose (76 Gy) conformal radiotherapy in moderate high-risk
      prostate cancer patients. Stratification will be performed by prognostic factors and by
      participating institution.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical Disease Free Survival: Estimated Percentage of Participants With Biochemical Disease-free Survival at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Biochemical relapse was defined as the time from inclusion in the study (randomization) until the patient meets criteria for Biochemical failure (Phoenix criteria: PSA nadir plus 2 ng/ml).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metastasis Free Survival: Estimated Percentage of Participants With Metastasis-free Survival at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Metastasis free survival: defined as the time from inclusion in the study (randomization) until the appearance of distant metastases: a positive result in any of the tests performed (scintigraphy, chest radiography, thorax, abdominal and pelvic CT and MRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival: Estimated Percentage of Participants Alive at 5 Years</measure>
    <time_frame>5 years</time_frame>
    <description>Overall Survival: defined as the time that elapses from the patient enters the study until the patient dies from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Cause-specific survival included all deaths from prostate cancer or treatment complications, and deaths from unknown causes in patients with either active cancer or a previously documented relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Defined as the maximal rectal, urinary and cardiovascular (CV) toxicity per patient more than 90 days after completion of RT.
Scoring scales used were the radiation morbidity scoring criteria of the European Organization for Research and Treatment of Cancer-Radiation Therapy Oncology Group (EORTC/RTOG) and the Common Terminology Criteria for Adverse Events (CTCAEs) v 3.0 for the remained toxicity.
CV events were defined according to the World Health Organization criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">362</enrollment>
  <condition>Prostate Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Long term androgen deprivation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short term androgen deprivation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Short term androgen deprivation</intervention_name>
    <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months</description>
    <arm_group_label>Short term androgen deprivation</arm_group_label>
    <other_name>Neoadjuvant and concomitant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long term androgen deprivation</intervention_name>
    <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy</description>
    <arm_group_label>Long term androgen deprivation</arm_group_label>
    <other_name>Neoadjuvant, concomitant and adjuvant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Short term androgen deprivation</intervention_name>
    <description>Minimum dose of 76 Gy (range 76-82 Gy)</description>
    <arm_group_label>Short term androgen deprivation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Long term androgen deprivation</intervention_name>
    <description>Minimum dose of 76 Gy (range 76-82 Gy)</description>
    <arm_group_label>Long term androgen deprivation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological proven adenocarcinoma of the prostate

          -  Stage: cT1c-3b N0M0 according to American Joint Committee on Cancer (AJCC) Tumor Node
             Metastasis (TNM)

          -  Prostatic Specific Antigen (PSA)&lt;100 ng/ml

          -  Intermediate (T1-T2 with Gleason Score [GS] 7 and/or PSA 10-20)

          -  High risk (T3 and/or GS 8-10 and/or PSA &gt; 20)

          -  Karnofsky Index (KI) performance status ≥70%

          -  Written informed consent

        Exclusion Criteria:

          -  T4 N1 M1,

          -  Previous surgical treatment (prostatectomy or cryosurgery)

          -  Neoadjuvant hormonal treatment &gt; 3 months.

          -  History of pelvic radiotherapy (RT)

          -  Contraindications for radiotherapy

          -  Concomitant use of chemotherapy

          -  Serious psychiatric or medical condition

          -  Current synchronic malignancies
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Almudena Zapatero, MD PhD, IP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo de Investigación Clínica en Oncología Radioterapia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105.</citation>
    <PMID>12128107</PMID>
  </results_reference>
  <results_reference>
    <citation>Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500.</citation>
    <PMID>9635694</PMID>
  </results_reference>
  <results_reference>
    <citation>Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001 Sep;166(3):876-81. Erratum in: J Urol 2001 Nov;166(5):1839.</citation>
    <PMID>11490237</PMID>
  </results_reference>
  <results_reference>
    <citation>Vicini FA, Abner A, Baglan KL, Kestin LL, Martinez AA. Defining a dose-response relationship with radiotherapy for prostate cancer: is more really better? Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1200-8.</citation>
    <PMID>11728678</PMID>
  </results_reference>
  <results_reference>
    <citation>Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35.</citation>
    <PMID>12243818</PMID>
  </results_reference>
  <results_reference>
    <citation>Leibel SA, Fuks Z, Zelefsky MJ, Hunt M, Burman CM, Mageras GS, Chui CS, Jackson A, Amols HI, Ling CC. Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol. 2003 Oct;30(5):596-615. Review.</citation>
    <PMID>14571409</PMID>
  </results_reference>
  <results_reference>
    <citation>Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NH, Zagars GK, Meistrich ML, Pollack A. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 1997 Jul 15;38(5):1071-7.</citation>
    <PMID>9276374</PMID>
  </results_reference>
  <results_reference>
    <citation>Zietman AL, Prince EA, Nakfoor BM, Shipley WU. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate: experimental and clinical results. Urology. 1997 Mar;49(3A Suppl):74-83. Review.</citation>
    <PMID>9123741</PMID>
  </results_reference>
  <results_reference>
    <citation>Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002 Jul 13;360(9327):103-6.</citation>
    <PMID>12126818</PMID>
  </results_reference>
  <results_reference>
    <citation>Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52.</citation>
    <PMID>11483335</PMID>
  </results_reference>
  <results_reference>
    <citation>Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):937-46.</citation>
    <PMID>11240234</PMID>
  </results_reference>
  <results_reference>
    <citation>Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998 Jun;159(6):2030-4.</citation>
    <PMID>9598512</PMID>
  </results_reference>
  <results_reference>
    <citation>Zagars GK, Johnson DE, von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study. Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1085-91.</citation>
    <PMID>3133327</PMID>
  </results_reference>
  <results_reference>
    <citation>Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90.</citation>
    <PMID>15817329</PMID>
  </results_reference>
  <results_reference>
    <citation>Jani AB, Basu A, Abdalla I, Connell PP, Krauz L, Vijayakumar S. Impact of hormone therapy when combined with external beam radiotherapy for early-stage, intermediate-, or high-risk prostate cancer. Am J Clin Oncol. 2003 Aug;26(4):382-5.</citation>
    <PMID>12902891</PMID>
  </results_reference>
  <results_reference>
    <citation>Nguyen KH, Horwitz EM, Hanlon AL, Uzzo RG, Pollack A. Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer? Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):377-83.</citation>
    <PMID>12957248</PMID>
  </results_reference>
  <results_reference>
    <citation>Zapatero A, Valcárcel F, Calvo FA, Algás R, Béjar A, Maldonado J, Villá S. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. J Clin Oncol. 2005 Sep 20;23(27):6561-8.</citation>
    <PMID>16170164</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <results_first_submitted>May 4, 2016</results_first_submitted>
  <results_first_submitted_qc>September 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2016</results_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patients with prostate adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between Nov 7, 2005, and Dec 20, 2010, 362 were registered. Of these, seven did not meet the inclusion criteria. The final trial population thus consisted of 355 men, of whom 178 were randomly assigned to the short-term androgen deprivation group and 177 to the long-term androgen deprivation group.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Long Term Androgen Deprivation</title>
          <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
        </group>
        <group group_id="P2">
          <title>Short Term Androgen Deprivation</title>
          <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Short term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
- Bicalutamide 50 mg tablet every day for 2 months
Short term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="177"/>
                <participants group_id="P2" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="163"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Long Term Androgen Deprivation</title>
          <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
        </group>
        <group group_id="B2">
          <title>Short Term Androgen Deprivation</title>
          <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Short term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
- Bicalutamide 50 mg tablet every day for 2 months
Short term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="177"/>
            <count group_id="B2" value="178"/>
            <count group_id="B3" value="355"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="56" upper_limit="82"/>
                    <measurement group_id="B2" value="72" lower_limit="54" upper_limit="85"/>
                    <measurement group_id="B3" value="71" lower_limit="54" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="178"/>
                    <measurement group_id="B3" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk subgroup (intermediate vs. high)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>T stage (categorical)</title>
          <description>Patients were staged according to the AJCC Cancer Staging criteria, 6th edition. Intermediate-risk and high-risk factors were defined following the 2005 guidelines of the National Comprehensive Cancer Network.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>T1: tumor neither palpable not visible by imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T2: Tumor confinent whitin prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T3: Tumor extends through the prostate capsule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA (continous)</title>
          <units>nanogrames per milliliter (ng/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.1" lower_limit="3.1" upper_limit="72.0"/>
                    <measurement group_id="B2" value="11.0" lower_limit="3.4" upper_limit="66.0"/>
                    <measurement group_id="B3" value="11" lower_limit="3.1" upper_limit="72.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PSA (categorical)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;10 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10-20 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;20 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gleason score (categorical)</title>
          <description>Gleason classification for prostate cancer were used considering Gleason 6 as less aggressive and Gleason 10 most aggressive</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive biopsy samples (continous)</title>
          <units>number of cylindres</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" lower_limit="1" upper_limit="13"/>
                    <measurement group_id="B2" value="4" lower_limit="1" upper_limit="16"/>
                    <measurement group_id="B3" value="4" lower_limit="1" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate radiotherapy dose (continous)</title>
          <units>Grays (Gy)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.0" lower_limit="30.6" upper_limit="88.4"/>
                    <measurement group_id="B2" value="78.0" lower_limit="64.0" upper_limit="82.2"/>
                    <measurement group_id="B3" value="78.0" lower_limit="30.6" upper_limit="88.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prostate radiotherapy dose (categorical)</title>
          <description>173 evaluable patients in short term group and 171 in the long term group</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;78 Gy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 78 Gy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pelvic radiotherapy (categorical)</title>
          <description>173 evaluable patients in short term group and 171 in the long term group</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Biochemical Disease Free Survival: Estimated Percentage of Participants With Biochemical Disease-free Survival at 5 Years</title>
        <description>Biochemical relapse was defined as the time from inclusion in the study (randomization) until the patient meets criteria for Biochemical failure (Phoenix criteria: PSA nadir plus 2 ng/ml).</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Long Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
          <group group_id="O2">
            <title>Short Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Short term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
- Bicalutamide 50 mg tablet every day for 2 months
Short term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Disease Free Survival: Estimated Percentage of Participants With Biochemical Disease-free Survival at 5 Years</title>
          <description>Biochemical relapse was defined as the time from inclusion in the study (randomization) until the patient meets criteria for Biochemical failure (Phoenix criteria: PSA nadir plus 2 ng/ml).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="87" upper_limit="92"/>
                    <measurement group_id="O2" value="81" lower_limit="78" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>3.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Metastasis Free Survival: Estimated Percentage of Participants With Metastasis-free Survival at 5 Years</title>
        <description>Metastasis free survival: defined as the time from inclusion in the study (randomization) until the appearance of distant metastases: a positive result in any of the tests performed (scintigraphy, chest radiography, thorax, abdominal and pelvic CT and MRI).</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Long Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
          <group group_id="O2">
            <title>Short Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Short term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
- Bicalutamide 50 mg tablet every day for 2 months
Short term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Metastasis Free Survival: Estimated Percentage of Participants With Metastasis-free Survival at 5 Years</title>
          <description>Metastasis free survival: defined as the time from inclusion in the study (randomization) until the appearance of distant metastases: a positive result in any of the tests performed (scintigraphy, chest radiography, thorax, abdominal and pelvic CT and MRI).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O2" value="83" lower_limit="80" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>3.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival: Estimated Percentage of Participants Alive at 5 Years</title>
        <description>Overall Survival: defined as the time that elapses from the patient enters the study until the patient dies from any cause.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Long Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
          <group group_id="O2">
            <title>Short Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Short term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
- Bicalutamide 50 mg tablet every day for 2 months
Short term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival: Estimated Percentage of Participants Alive at 5 Years</title>
          <description>Overall Survival: defined as the time that elapses from the patient enters the study until the patient dies from any cause.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="93" upper_limit="97"/>
                    <measurement group_id="O2" value="86" lower_limit="83" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.31</ci_lower_limit>
            <ci_upper_limit>4.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cause-specific Survival</title>
        <description>Cause-specific survival included all deaths from prostate cancer or treatment complications, and deaths from unknown causes in patients with either active cancer or a previously documented relapse</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Long Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
          <group group_id="O2">
            <title>Short Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Short term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
- Bicalutamide 50 mg tablet every day for 2 months
Short term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Cause-specific Survival</title>
          <description>Cause-specific survival included all deaths from prostate cancer or treatment complications, and deaths from unknown causes in patients with either active cancer or a previously documented relapse</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177"/>
                    <measurement group_id="O2" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Toxicity</title>
        <description>Defined as the maximal rectal, urinary and cardiovascular (CV) toxicity per patient more than 90 days after completion of RT.
Scoring scales used were the radiation morbidity scoring criteria of the European Organization for Research and Treatment of Cancer–Radiation Therapy Oncology Group (EORTC/RTOG) and the Common Terminology Criteria for Adverse Events (CTCAEs) v 3.0 for the remained toxicity.
CV events were defined according to the World Health Organization criteria</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Long Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
          <group group_id="O2">
            <title>Short Term Androgen Deprivation</title>
            <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Short term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
- Bicalutamide 50 mg tablet every day for 2 months
Short term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
          </group>
        </group_list>
        <measure>
          <title>Late Toxicity</title>
          <description>Defined as the maximal rectal, urinary and cardiovascular (CV) toxicity per patient more than 90 days after completion of RT.
Scoring scales used were the radiation morbidity scoring criteria of the European Organization for Research and Treatment of Cancer–Radiation Therapy Oncology Group (EORTC/RTOG) and the Common Terminology Criteria for Adverse Events (CTCAEs) v 3.0 for the remained toxicity.
CV events were defined according to the World Health Organization criteria</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 2 of more rectal toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2 of more urinary toxicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>63 months (IQR 50–82)</time_frame>
      <desc>Maximum toxicity per patient</desc>
      <group_list>
        <group group_id="E1">
          <title>Long Term Androgen Deprivation</title>
          <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Long term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
        </group>
        <group group_id="E2">
          <title>Short Term Androgen Deprivation</title>
          <description>Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
High dose conformal radiotherapy
Short term androgen deprivation: - Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
- Bicalutamide 50 mg tablet every day for 2 months
Short term androgen deprivation: Minimum dose of 76 Gy (range 76–82 Gy)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Miocardial Infarction/Ischemic disease</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="177"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="177"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Second malignancies</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="177"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Tromboembolic disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="177"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident (CVA)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="177"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <description>Grade 2 or more according EORTC/RTOG and CTCAE v 3.0</description>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="177"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="177"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <description>Grade 2 or more according EORTC/RTOG and CTCAE v 3.0</description>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="177"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary toxicity</sub_title>
                <description>Grade 2 or more according EORTC/RTOG and CTCAE v 3.0</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="177"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Relatively short follow-up and low number of events.
The lack of patient-reported outcomes.
Our decision to include vascular events other than strictly cardiac events (e.g. the presence of CVA or thromboembolic disease).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Almudena Zapatero</name_or_title>
      <organization>Hospital Universitario de la Princesa; Health Research Institute IIS from Hospital Universitario de la Princesa</organization>
      <phone>+34 91 520 23 15</phone>
      <email>almudena.zapatero@salud.madrid.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

